Haematological manifestations of lupus

被引:181
作者
Fayyaz, Anum [1 ,2 ,3 ]
Igoe, Ann [1 ,2 ,4 ,5 ]
Kurien, Biji T. [1 ,2 ,3 ]
Danda, Debashish [1 ,6 ]
James, Judith A. [1 ,2 ,3 ]
Stafford, Haraldine A. [7 ]
Scofield, R. Hal [1 ,2 ,3 ]
机构
[1] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA
[3] Dept Vet Affairs Med Ctr, Med Serv, Oklahoma City, OK USA
[4] Metro Hlth Syst, Dept Med, Cleveland, OH USA
[5] Metro Hlth Syst, Dept Pediat, Cleveland, OH USA
[6] Christian Med Ctr, Dept Rheumatol, Vellore, Tamil Nadu, India
[7] Univ Iowa, Dept Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA
来源
LUPUS SCIENCE & MEDICINE | 2015年 / 2卷 / 01期
基金
美国国家卫生研究院;
关键词
D O I
10.1136/lupus-2014-000078
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our purpose was to compile information on the haematological manifestations of systemic lupus erythematosus (SLE), namely leucopenia, lymphopenia, thrombocytopenia, autoimmune haemolytic anaemia (AIHA), thrombotic thrombocytopenic purpura (TTP) and myelofibrosis. During our search of the English-language MEDLINE sources, we did not place a date-of-publication constraint. Hence, we have reviewed previous as well as most recent studies with the subject heading SLE in combination with each manifestation. Neutropenia can lead to morbidity and mortality from increased susceptibility to infection. Severe neutropenia can be successfully treated with granulocyte colony-stimulating factor. While related to disease activity, there is no specific therapy for lymphopenia. Severe lymphopenia may require the use of prophylactic therapy to prevent select opportunistic infections. Isolated idiopathic thrombocytopenic purpura maybe the first manifestation of SLE by months or even years. Some manifestations of lupus occur more frequently in association with low platelet count in these patients, for example, neuropsychiatric manifestation, haemolytic anaemia, the antiphospholipid syndrome and renal disease. Thrombocytopenia can be regarded as an important prognostic indicator of survival in patients with SLE. Medical, surgical and biological treatment modalities are reviewed for this manifestation. First-line therapy remains glucocorticoids. Through our review, we conclude glucocorticoids do produce a response in majority of patients initially, but sustained response to therapy is unlikely. Glucocorticoids are used as first-line therapy in patients with SLE with AIHA, but there is no conclusive evidence to guide second-line therapy. Rituximab is promising in refractory and non-responding AIHA. TTP is not recognised as a criteria for classification of SLE, but there is a considerable overlap between the presenting features of TTP and SLE, and a few patients with SLE have concurrent TTP. Myelofibrosis is an uncommon yet well-documented manifestation of SLE. We have compiled the cases that were reported in MEDLINE sources.
引用
收藏
页数:18
相关论文
共 181 条
  • [11] A polymorphism in human platelet antigen 6b and risk of thrombocytopenia in patients with systemic lupus erythematosus
    Amengual, Olga
    Atsumi, Tatsuya
    Komano, Yukiko
    Kataoka, Hiroshi
    Horita, Tetsuya
    Yasuda, Shinsuke
    Koike, Takao
    [J]. ARTHRITIS AND RHEUMATISM, 2007, 56 (08): : 2803 - 2805
  • [12] THROMBOTIC THROMBOCYTOPENIC PURPURA - REPORT OF 16 CASES AND REVIEW OF LITERATURE
    AMOROSI, EL
    ULTMANN, JE
    [J]. MEDICINE, 1966, 45 (02) : 139 - +
  • [13] SELECTIVE-INHIBITION OF GRANULOPOIESIS WITH SEVERE NEUTROPENIA IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    ARENAS, M
    ABAD, A
    VALVERDE, V
    FERRIZ, P
    PASCUAL, R
    [J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (08): : 979 - 980
  • [14] Arnal C, 2002, J RHEUMATOL, V29, P75
  • [15] Aziz AR, 2004, CLIN ADV HEMATOL ONC, V2, P69
  • [16] Aziz Ashraf R, 2004, Clin Adv Hematol Oncol, V2, P467
  • [17] PATHOGENIC AUTOANTIBODIES IN THE NZB MOUSE ARE SPECIFIC FOR ERYTHROCYTE BAND-3 PROTEIN
    BARKER, RN
    OLIVEIRA, GGD
    ELSON, CJ
    LYDYARD, PM
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (07) : 1723 - 1726
  • [18] BHUYAN UN, 1978, INDIAN J MED RES, V67, P269
  • [19] Blanco R, 1997, BRIT J RHEUMATOL, V36, P1095
  • [20] INTERMITTENT CYCLOPHOSPHAMIDE FOR THE TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    BOUMPAS, DT
    BAREZ, S
    KLIPPEL, JH
    BALOW, JE
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 112 (09) : 674 - 677